Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528 in Healthy Adult Volunteers

Study identifier:MI-CP105

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability,Immunogenicity, and Pharmacokinetics of MEDI-528, a Humanized Monoclonal Anti-Interleukin-9 Antibody, in Healthy Adult Volunteers

Medical condition

asthma

Phase

Phase 1

Healthy volunteers

Yes

Study drug

Sex

All

Actual Enrollment

Study type

Interventional

Age

18 Years - 49 Years

Date

Study Start Date: 01 Aug 2004

Primary Completion Date: 01 Feb 2005

Study Completion Date: 01 Mar 2005

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Feb 2014 by MedImmune

Collaborators

"N/A"

Inclusion and exclusion criteria

Inclusion Criteria

- Males and females age 18 up to and including 49 years of age at the time of the first dose of
study drug
- Weight < 89 kg
- Written informed consent obtained from the volunteer
- Healthy by medical history and physical examination
- Sexually active females, unless surgically sterile or at least one year post-menopausal, must use an effective method of avoiding pregnancy (including oral, injectable, transdermal or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap,abstinence, use of a condom by the sexual partner or sterile sexual partner) for 3 months before the first dose of study drug, and must agree to continue using such precautions
through 84 days after their dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician. Sexually active males, unless surgically sterile, must likewise use an effective method of birth control (condom or abstinence) and must agree to continue using such precautions through 84 days after their dose of study drug.
- Use of common over-the-counter medications such as topical corticosteroids, decongestants, antihistamines, analgesics, and antacids is permitted unless, in the opinion of the investigator, it would interfere with either the volunteer’s ability to complete the study or interpretation of
study results.
- Ability to complete the follow-up period of 84 days
- Willing to forego other forms of experimental treatment during the study period of 84 days

Exclusion Criteria

- Acute illnesses or evidence of significant active infection, such as fever ≥38.0°C (100.5°F) at the start of the study
- Use of prescription medications, other than contraceptives, in the 28-day period before Study Day 0
- Blood donation in excess of 400 mL within 6 months of the time of entry into the study
- History of use of tobacco products within 3 years of Study Day 0 or history of smoking of >10 pack-years
- History of immunodeficiency or receipt or current use of immunosuppressive drugs including systemic corticosteroids
- History of allergic disease or reactions likely to be exacerbated by any component of the Study Drug (described in the Investigator’s Brochure)
- History of substance abuse that, in the opinion of the investigator, may compromise the ability of the study subject to complete the study and follow-up period
- Evidence of any systemic disease on physical examination
- Evidence of infection with hepatitis A, B, or C virus or HIV-1
- Receipt of immunoglobulins or blood products within 60 days of entering the study
- Receipt of any investigational drug therapy within 60 days of the first dose of study drug through Study Day 84 (use of licensed agents for indications not listed in the package insert is permitted)
- Any of the following: CBC: Hgb < 12.0 gm/dL; WBC < 4,000/mm3; platelet count <125,000/mm3 (or laboratory normal values); Na, K, Cl, CO2, AST, ALT, BUN, 4-hour fasting glucose, amylase, lipase, creatinine, troponin > upper limit of normal; other abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant.
- Clinically significant abnormality, as determined by the investigator, on 12-lead electrocardiogram at the time of initial screening
- Elective surgery planned during the study period through Study Day 84
- Pregnancy (sexually active females must have a negative serum pregnancy test on the day of the first dose of the study drug, before dosing)
- Nursing mother
- The presence of any acute or chronic organ-specific condition or any concern, which in the opinion of the investigator, may interfere with the conduct or interpretation of the study

No locations available

Arms	Assigned Interventions
Experimental: MEDI-528 0.3 mg/kg MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose	Biological/Vaccine: MEDI-528 0.3 mg/kg MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
Experimental: MEDI-528 1 mg/kg MEDI-528 (1 mg/kg) administered as a single, IV dose	Biological/Vaccine: MEDI-528 1 mg/kg MEDI-528 (1 mg/kg) administered as a single, IV dose
Experimental: MEDI-528 3 mg/kg MEDI-528 (3 mg/kg) administered as a single, IV dose	Biological/Vaccine: MEDI-528 3 mg/kg MEDI-528 (3 mg/kg) administered as a single, IV dose
Experimental: MEDI-528 9 mg/kg MEDI-528 (9 mg/kg) administered as a single, IV dose	Biological/Vaccine: MEDI-528 9 mg/kg MEDI-528 (9 mg/kg) administered as a single, IV dose

Documents available

Trial Results Summaries
Available here

Contacts

Contact

MedImmune Contact

301-398-0000

[email protected]

Investigators

Principal Investigator

Ramon Vargas

Unaffiliated